指南与共识细菌感染、耐药与抗菌药物

新生儿口服与静脉阿莫西林给药建议:一项汇总群体药代动力学研究

Oral and Intravenous Amoxicillin Dosing Recommendations in Neonates: A Pooled Population Pharmacokinetic Study.
指南 / 共识 · Clin Infect Dis · 2023-01-01

该汇总群体药代动力学研究合并3个数据集,纳入261例(口服79例、静脉182例)新生儿,中位胎龄35.8周、体重2.6 kg,构建一室模型并模拟不同给药方案。结果显示口服生物利用度为87%,出生后30周以上新生儿清除率随日龄增加,生后第一周口服或静脉50 mg/kg/日分2次给药优于分3或4次。作者认为口服阿莫西林可作为全球新生儿经济有效且更友好的替代方案。

要点

  • 口服阿莫西林生物利用度为87%,生后第一周50 mg/kg/日分2次给药优于分3或4次。
  • 清除率随日龄增加:日龄10天为日龄3天的1.25倍,日龄20天为1.43倍。
  • 作者认为口服阿莫西林可作为全球新生儿经济有效且更友好的替代方案。

核心结论

  • 作者认为生后数周内接受口服阿莫西林的新生儿采用每日2次给药方案可达到 adequate 阿莫西林水平。
  • 作者认为口服阿莫西林治疗可作为全球新生儿经济有效且更友好的替代方案。

研究设计与样本

  • 汇总群体药代动力学研究,合并3个数据集进行非线性混合效应建模。
  • 队列共261例新生儿(口服79例、静脉182例),中位胎龄35.8周(范围24.9-42.4),中位体重2.6 kg(范围0.5-5)。
  • 采用一室模型加一级吸收描述阿莫西林药代动力学。

主要发现

  • 口服生物利用度为87%。
  • 出生后30周以上新生儿清除率(L/h/kg)随日龄增加:日龄10天为日龄3天的1.25倍,日龄20天为日龄3天的1.43倍。
  • 生后第一周,口服或静脉50 mg/kg/日分2次给药优于分3或4次给药。

关键数值与推荐

  • 目标为游离药物浓度超过最低抑菌浓度(MIC)的时间达50%,MICECOFF为8 mg/L(覆盖大肠埃希菌等革兰阴性菌)。
  • 推荐生后第一周口服或静脉50 mg/kg/日分2次给药优于分3或4次给药。

临床怎么用

  • 作者认为生后数周内口服阿莫西林采用每日2次给药方案可达到 adequate 水平,可作为全球新生儿经济有效且更友好的替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a lack of evidence on oral amoxicillin pharmacokinetics and exposure in neonates with possible serious bacterial infection (pSBI). We aimed to describe amoxicillin disposition following oral and intravenous administration and to provide dosing recommendations for preterm and term neonates treated for pSBI. METHODS: In this pooled-population pharmacokinetic study, 3 datasets were combined for nonlinear mixed-effects modeling. In order to evaluate amoxicillin exposure following oral and intravenous administration, pharmacokinetic profiles for different dosing regimens were simulated with the developed population pharmacokinetic model. A target of 50% time of the free fraction above the minimal inhibitory concentration (MIC) with an MICECOFF of 8 mg/L (to cover gram-negative bacteria such as Escherichia coli) was used. RESULTS: The cohort consisted of 261 (79 oral, 182 intravenous) neonates with a median (range) gestational age of 35.8 weeks (range, 24.9-42.4) and bodyweight of 2.6 kg (range, 0.5-5). A 1-compartment model with first-order absorption best described amoxicillin pharmacokinetics. Clearance (L/h/kg) in neonates born after 30 weeks' gestation increased with increasing postnatal age (PNA day 10, 1.25-fold; PNA day 20, 1.43-fold vs PNA day 3). Oral bioavailability was 87%. We found that a twice-daily regimen of 50 mg/kg/day is superior to a 3- or 4-times daily schedule in the first week of life for both oral and intravenous administration. CONCLUSIONS: This pooled population pharmacokinetic description of intravenous and oral amoxicillin in neonates provides age-specific dosing recommendations. We conclude that neonates treated with oral amoxicillin in the first weeks of life reach adequate amoxicillin levels following a twice-daily dosing regimen. Oral amoxicillin therapy could therefore be an adequate, cost-effective, and more patient-friendly alternative for neonates worldwide.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Keij FM, Schouwenburg S, Kornelisse RF, et al. Oral and Intravenous Amoxicillin Dosing Recommendations in Neonates: A Pooled Population Pharmacokinetic Study. Clin Infect Dis. 2023. PMID: 37757471. doi:10.1093/cid/ciad432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。